The notices it replaced
- Reissues: PAR-24-124 NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- 2 steps back: PAR-20-218 NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- 3 steps back: PAR-18-829 NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- 4 steps back: PAR-17-319 NCCIH Natural Product Phase I-IIa Clinical Trial Phased Innovation Award (R61/R33)
- 5 steps back: PAR-16-418 Exploratory Clinical Trials and Studies of Natural Products in NCCIH High Priority Research Topics (R61/R33)
- 6 steps back: RFA-AT-16-001 Phased Innovation Award for Exploratory Clinical Trials of Natural Products in NCCIH High Priority Research Topics (R21/R33)
Who won it before
16 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,492,801 in first-year total cost, median $329,621.
Most frequent study sections
- Special Emphasis Panel[ZAT1 VS (08)]6
- Special Emphasis Panel[ZAT1 SM (38)]3
- Special Emphasis Panel[ZAT1 YW (01)]2
- Special Emphasis Panel[ZAT1 MH (01)]1
- Special Emphasis Panel[ZAT1 SH (01)]1
Most frequent institutions
- BAYLOR COLLEGE OF MEDICINE1
- CASE WESTERN RESERVE UNIVERSITY1
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
- GEORGETOWN UNIVERSITY1
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Probiotic Administration for Adolescent Depression1R61AT012028-01A1 · under PAR-20-218 | LEUNG, CHERRYYANG, TONY TUNG-I | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $564,763 | ZAT1 |
| 2022 | Randomized placebo controlled trial to determine the biological signature of cannabidiol as a treatment for social anxiety disorder1R61AT012026-01 · under PAR-20-218 | BLESSING, ESTHER MARIANSIMON, NAOMI M | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $591,682 | ZAT1 |
| 2022 | Endocannabinoid System Engagement and Clinical Symptom Change with Cannabidiol for Social Anxiety Disorder1R61AT011735-01 · under PAR-20-218 | STEIN, MURRAY B.TAYLOR, CHARLES | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $551,121 | ZAT1 |
| 2020 | 31P-MRS and resting state functional connectivity analysis of the effects of 5-hydroxytryptophan and creatine for antidepressant augmentation in patients with SSRI/SNRI-resistant major depressive diso1R61AT010636-01A1 · under PAR-18-829 | KIOUS, BRENT MICHAELRENSHAW, PERRY FRANKLIN | UNIVERSITY OF UTAH, UT | $381,055 | ZAT1 |
| 2019 | A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects1R61AT009988-01A1 · under PAR-18-829 | MATHEWS, CAROL AXING, CHENGGUO | UNIVERSITY OF FLORIDA, FL | $378,341 | ZAT1 |
| 2018 | Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics1R61AT009622-01A1 · under PAR-17-319 | FRASER, CLAIRE M.MERENSTEIN, DANIEL J | GEORGETOWN UNIVERSITY, DC | $392,910 | ZAT1 |
| 2018 | Development of Pregnenolone as a Treatment for Depression1R61AT009625-01A1 · under PAR-17-319 | BROWN, E SHERWOOD | UT SOUTHWESTERN MEDICAL CENTER, TX | $336,791 | ZAT1 |
| 2018 | Ginger's therapeutic potential in asthma1R61AT009989-01 · under PAR-17-319 | DIMANGO, EMILYEMALA, CHARLES W | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $332,175 | ZAT1 |
| 2018 | Impact of quercetin on inflammatory and oxidative stress markers in COPD1R61AT009991-01 · under PAR-17-319 | MARCHETTI, NATHANIELSAJJAN, UMADEVI SIVANAPPA | TEMPLE UNIV OF THE COMMONWEALTH, PA | $311,595 | ZAT1 |
| 2018 | Prebiotic Treatment in People with Schizophrenia1R61AT009990-01 · under PAR-17-319 | BUCHANAN, ROBERT W | UNIVERSITY OF MARYLAND BALTIMORE, MD | $308,878 | ZAT1 |
| 2018 | Identifying Biological Signatures of N-acetylcysteine for Non-Suicidal Self-Injury in Adolescents1R61AT009995-01 · under PAR-17-319 | CULLEN, KATHRYN REGAN | UNIVERSITY OF MINNESOTA, MN | $307,912 | ZAT1 |
| 2017 | Fatty acid supplements alter biological signatures in children with Autism Spectrum Disorder1R61AT009632-01 · under PAR-16-418 | KEIM, SARAHROGERS, LYNETTE KAY | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $327,066 | ZAT1 |
| 2017 | Biological signatures of the cognitive effects of Centella asiatica1R61AT009628-01 · under PAR-16-418 | QUINN, JOSEPH FSOUMYANATH, AMALA | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $73,000 | ZAT1 |
| 2016 | Role of Zinc in HIV inflammation1R21AT009153-01 · under RFA-AT-16-001 | MCCOMSEY, GRACE A | CASE WESTERN RESERVE UNIVERSITY, OH | $226,110 | ZAT1 |
| 2016 | Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children with Functional Abdominal Pain1R21AT009101-01 · under RFA-AT-16-001 | SHULMAN, ROBERT J | BAYLOR COLLEGE OF MEDICINE, TX | $218,158 | ZAT1 |
| 2016 | Phased Exploratory Clinical Studies of Harpagophytum procumbens’ Impact upon the Biological Signature of Inflammatory Osteoarthritis1R21AT009086-01 · under RFA-AT-16-001 | FOLK, WILLIAM ROBERTGERKOVICH, MARY M. | UNIVERSITY OF MISSOURI KANSAS CITY, MO | $191,244 | ZAT1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.